Enhanced bioavailability of zeaxanthin in a milk-based formulation of wolfberry (Gou Qi Zi; Fructus barbarum L.)

British Journal of Nutrition

Volumn 96, Issue 1, 2006, Pages 154-160

  Benzie, Iris F F ^a   Chung, Wai Y ^a   Wang, Junkuan ^b   Richelle, Myriam ^b   Bucheli, Peter ^c  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

^c GE (Shanghai) Ltd   (China)

Author keywords

Chinese medicine; Gou Qi Zi; Kei Tze; Macular degeneration; Wolfberry; Zeaxanthin

Indexed keywords

HOT WATER; LYCEUM BARBARUM EXTRACT; PLANT MEDICINAL PRODUCT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZEAXANTHIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL MILK; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; FREEZE DRYING; FRUIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LYCEUM BARBARUM; MEAL; MILK; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TEMPERATURE DEPENDENCE;

EID: 33746774657     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1079/BJN20061796     Document Type: Article

References (48)

1. Aebischer CP, Schierle J & Schüep W (1999) Simultaneous determination of retinol, tocopherols, carotene, lycopene, and xanthophylls in plasma by means of reversed-phase high-performance liquid chromatography. Methods Enzymol 299, 348-362.
2. Bai S (1999) Research on Ningxia Wolfberry (Lycium barbarum), vols. 1 and 2. Ningxia, China: People's Publishing House.
3. Bartlett H & Eperjesi F (2003) Age-related macular degeneration and nutritional supplementation: a review of randomized controlled trials. Ophthal Physiol Opt 23, 383-399.
4. Beatty S, Boulton M, Henson D, Koh HH & Murray IJ (1999) Macular pigment and age related macular degeneration. Br J Ophthalmol 83, 867-877.
5. Beatty S, Koh H, Henson D & Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular. Surv Ophthalmol 45, 115-134.
6. Benzie IFF (2003) Evolution of dietary antioxidants. J Compar Biochem Physiol 136, 113-126.
7. Bone RA, Landrum JT, Dixon Z, Chen Y & Llerena CM (2000) Lutein and zeaxanthin in the eyes, serum and diet of human subjects. Exp Eye Res 71, 239-245.
8. Bone RA, Landrum JT, Guerra LH & Ruiz CA (2003) Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 133, 992-998.
9. Breithaupt DE, Weller P, Wolters M & Hahn A (2004) Comparison of plasma responses in human subjects after the ingestion of 3R,3R′-zeaxanthin dipalmitate from wolfberry (Lycium barbarum) and non-esterified 3R,3R′-zeaxanthin using chiral high-performance liquid chromatography. Br J Nutr 91, 707-713.
10. Cheng CY, Chung WY, Szeto YT & Benzie IFF (2005) Fasting plasma zeaxanthin response to Fructus barbarum L. (wolfberry; Kei Tze) in a food-based human supplementation trial. Br J Nutr 93, 123-130.
11. Curcio CA, Owsley C & Jackson GR (2000) Spare the rods, save the cones in aging and age-related maculopathy. Invest Ophthalmol Vis Sci 41, 2015-2018.
12. Dwyer JH, Paul-Labrador MJ, Fan J, Shircore AM, Metz CNB & Dwyer KM (2004) Progression of carotid intima-media thickness and plasma antioxidants: The Los Angeles Atherosclerosis Study. Arterioscler Thromb Vasc Biol 24, 313-319.
13. Gonzalez S, Astner S, An W, Goukassian D & Pathak MA (2003) Dietary lutein/zeaxanthin decreases ultraviolet B-induced epidermal hyperproliferation and acute inflammation in hairless mice. J Invest Dermatol 121, 399-405.
14. Hammond BR Jr, Johnson EJ, Russell RM, Krinsky NI, Yeum KJ, Edwards RB & Snodderly DM (1997) Dietary modification of human macular pigment. Invest Opthalmol Vis Sci 38, 1795-1901.
15. Handelman GJ, Dratz EA, Reay CC & van Kuijk JG (1988) Carotenoids in the human macula and whole retina. Invest Ophthalmol Vis Sci 29, 850-855.
16. Handlelman GJ, Nightingale ZD, Lichenstein AH, Scaefer EJ & Blumberg JB (1999) Lutein and zeaxanthin in plasma after dietary supplementation with egg yolk. Am J Clin Nutr 70, 247-251.
17. Hartmann D, Thurmann PA, Spitzer V, Schalch W, Manner B & Cohn W (2004) Plasma kinetics of zeaxanthin and 3′-dehydro-lutein after multiple oral doses of synthetic zeaxanthin. Am J Clin Nutr 79, 410-417.
18. Hubacek JA, Berge KE, Stefkova J, Pitha J, Skodova Z, Lanska V & Poledne R (2004) Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol levels. Physiol Res 53, 395-401.
19. Humphries JA & Khachik F (2003) Distribution of lutein, zeaxanthin, and related geometrical isomers in fruit, vegetables, wheat and pasta products. J Agric Food Chem 51, 1322-1327.
20. Hyman L & Neborsky R (2002) Risk factors for age-related macular degeneration: an update. Curr Opin Ophthalmol 13, 171-175.
21. Krinsky NI, Landrum JT & Bone RA (2003) Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Ann Rev Nutr 23, 171-201.
22. Lam KW & But P (1999) The content of zeaxanthin in Gou Qi Zi, a potential health benefit to improve visual acuity. Food Chem 67, 173-176.
23. Landrum JT & Bone RA (2001) Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 385, 28-40.
24. Landrum JT, Bone RA, Joa H, Joa H, Kilburn MD, Moore LL & Sprague KE (1997) A one year study of the macular pigment: the effect of 140 days of a lutein supplement. Exp Eye Res 65, 57-62.
25. Landrum JT, Bone RA, Moore LL & Gomez CM (1999) Analysis of zeaxanthin distribution within individual human retinas. Methods Enzymol 299, 457-467.
26. Le Marchand L, Hankin JH, Kolonel LN, Beecher GR, Wilkens LR & Zhao LP (1993) Intake of specific carotenoids and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2, 183-187.
27. Leung IYF, Tso MOM, Li WWY & Lam TT (2001) Absorption and tissue distribution of zoaxanthin and lutein in rhesus monkeys after taking Fructus lycii (Gou Qi Zi) extract. Invest Ophthalmol Vis Sci 42, 466-471.
28. Mares-Perlman JA, Millen AE, Ficek TL & Hankinson SE (2002) The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease: an overview. J Nutr 132, 518S-524S.
29. Miwa K, Inazu A, Kobayashi J, Higashikata T, Nohara A, Kawashiri M, Katsuda S, Takata M, Koizumi J & Mabuchi H (2005) ATP-binding cassette transporter G8 M429V polymorphism as a novel genetic marker of higher cholesterol absorption in hypercholesterolaemic Japanese subjects. Clin Sci 109, 183-188.
30. Moeller SM, Jacques PF & Blumberg JB (2000) The potential role of dietary xanthophylls in cataract and age-related macular degeneration. J Am Coll Nutr 19, Suppl. 5, 522S-527S.
31. Mozaffarieh M, Sacu S & Wedrich A (2003) The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: a review based on controversial evidence. Nutr J 2, 20-31.
32. Olmedilla B, Granado F, Bianco I, Vaquere M & Cajigal C (2001) Lutein in patients with cataracts and age-related macular degeneration: a long-term supplementation study. J Sci Food Agric 81, 904-909.
33. Parker RS, Swanson JE, You CS, Edwards AJ & Huang T (1999) Bioavailability of carotenoid in human subjects. Proc Nutr Soc 58, 155-162.
34. Pérez-Gálvez A, Martin HD, Sies H & Stahl W (2003) Incorporation of carotenoids from paprika oleoresin into human chylomicrons. Br J Nutr 89, 787-793.
35. Polidori MC, Cherubini A, Stahl W, Senin U, Sies H & Mecocci P (2002) Plasma carotenoid and malondialdehyde levels in ischemic stroke patients: relationship to early outcome. Free Radic Res 36, 265-268.
36. Puddu P, Cravero E, Puddu GM & Muscari A (2005) Genes and atherosclerosis: at the origin of the predisposition. Int J Clin Pract 59, 462-472.
37. Reboul E, Abou L, Mikail C, Gghiringhelli O, Andre M, Portugal H, Jourdheuil-Rahmani D, Amiot MJ, Lairou D & Borel P (2005) Lutein transport by Caco-2 TC-7 cells occurs partly by a facilitated process involving the scavenger receptor class B type I (SR-BI). Biochem J 387, 455-461.
38. Richelle M, Bortlik K, Liardet S, Hager C, Lambelet P, Baur M, Applegate LA & Offord EA (2002) A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste. J Nutr 132, 404-408.
39. Rose RC, Richer SP & Bode AM (1998) Ocular oxidants and antioxidant protection. PSEBM 217, 397-407.
40. Slattery ML, Benson J, Curtin K, Ma K, Shaeffer D & Potte RJD (2000) Carotenoids and colon cancer. Am J Clin Nutr 71, 575-592.
41. Sommerburg O, Keunen JE, Bird AC & van Kuijk FJ (1998) Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol 82, 907-910.
42. Stokkermans TJW (2000) Treatment of age-related macular degeneration. Clin Eye Vis Care 12, 15-35.
43. Terpstra AHM (1985) Isolation of serum chylomicrons prior to density gradient ultracentrifugation of other serum lipoprotein classes. Anal Biochem 150, 221-227.
44. van het Hof KH, West CE, Weststrate JA & Hautvast JGAJ (2000) Dietary factors that affect the bioavailability of carotenoids. J Nutr 130, 503-506.
45. Verschuren WM, Jacobs DR, Bloemberg BP, et al. (1995) Serum total cholesterol and long term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. JAMA 274, 131-136.
46. Weller P & Breithaupt DE (2003) Identification and quatification of zeaxanthin esters in plants using liquid chromatography-mass spectrometry. J Agric Food Chem 51, 7044-7049.
47. Woll PS, Hanson NQ, Arends VL & Tsai MY (2005) Effect of two common polymorphisms in the ATP binding cassette transporter A1 gene on HDL-cholesterol concentration. Clin Chem 51, 907-909.
48. Zhou L, Leung I, Tso MOM & Lam KW (1999) The identification of dipalmityl zeaxanthin as the major carotenoid in Gou Qi Zi by high pressure liquid chromatography and mass spectrometry. J Ocul Pharmacol Ther 15, 557-565.